Technical Analysis for KYTX - Kyverna Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 0.98% | |
| Lower Bollinger Band Walk | Weakness | 0.98% | |
| New 52 Week Low | Weakness | 0.98% |
| Alert | Time |
|---|---|
| Down 3% | about 3 hours ago |
| Fell Below Previous Day's Low | about 3 hours ago |
| Down 2 % | about 3 hours ago |
| Down 1% | about 3 hours ago |
| Rose Above Lower Bollinger Band | about 4 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1 trials in the United States and Germany for patients with lupus nephritis.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Sjögren Syndrome Lupus Nephritis Systemic Sclerosis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Sjögren Syndrome Lupus Nephritis Systemic Sclerosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.06 |
| 52 Week Low | 3.94 |
| Average Volume | 347,528 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 5.28 |
| 20-Day Moving Average | 4.96 |
| 10-Day Moving Average | 4.81 |
| Average True Range | 0.39 |
| RSI (14) | 31.97 |
| ADX | 16.56 |
| +DI | 18.01 |
| -DI | 30.30 |
| Chandelier Exit (Long, 3 ATRs) | 4.51 |
| Chandelier Exit (Short, 3 ATRs) | 5.12 |
| Upper Bollinger Bands | 5.78 |
| Lower Bollinger Band | 4.14 |
| Percent B (%b) | -0.01 |
| BandWidth | 32.98 |
| MACD Line | -0.29 |
| MACD Signal Line | -0.19 |
| MACD Histogram | -0.0947 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.56 | ||||
| Resistance 3 (R3) | 4.58 | 4.46 | 4.48 | ||
| Resistance 2 (R2) | 4.46 | 4.35 | 4.45 | 4.46 | |
| Resistance 1 (R1) | 4.29 | 4.28 | 4.23 | 4.27 | 4.43 |
| Pivot Point | 4.17 | 4.17 | 4.14 | 4.16 | 4.17 |
| Support 1 (S1) | 4.00 | 4.06 | 3.94 | 3.98 | 3.81 |
| Support 2 (S2) | 3.88 | 3.99 | 3.87 | 3.78 | |
| Support 3 (S3) | 3.71 | 3.88 | 3.76 | ||
| Support 4 (S4) | 3.69 |
